標(biāo)題: Titlebook: Breast Cancer Research and Treatment; Innovative Concepts Ouissam Al Jarroudi,Khalid El Bairi,Giuseppe Curig Book 2023 The Editor(s) (if ap [打印本頁] 作者: Corrugate 時間: 2025-3-21 18:09
書目名稱Breast Cancer Research and Treatment影響因子(影響力)
書目名稱Breast Cancer Research and Treatment影響因子(影響力)學(xué)科排名
書目名稱Breast Cancer Research and Treatment網(wǎng)絡(luò)公開度
書目名稱Breast Cancer Research and Treatment網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Breast Cancer Research and Treatment被引頻次
書目名稱Breast Cancer Research and Treatment被引頻次學(xué)科排名
書目名稱Breast Cancer Research and Treatment年度引用
書目名稱Breast Cancer Research and Treatment年度引用學(xué)科排名
書目名稱Breast Cancer Research and Treatment讀者反饋
書目名稱Breast Cancer Research and Treatment讀者反饋學(xué)科排名
作者: minimal 時間: 2025-3-21 21:14 作者: misanthrope 時間: 2025-3-22 03:08 作者: 恃強凌弱的人 時間: 2025-3-22 06:11
Growth Factors and Malignant Mesotheliomaerapy. Despite recent advances in drug discovery, its management is still a challenge for clinicians, illuminating the unmet need to develop novel treatment approaches. Antibody–drug conjugates (ADC) are innovative oncology drugs that combine the specificity of monoclonal antibodies and the high eff作者: Metastasis 時間: 2025-3-22 09:30 作者: boisterous 時間: 2025-3-22 15:28 作者: 現(xiàn)暈光 時間: 2025-3-22 18:08
https://doi.org/10.1007/978-3-319-99510-6ne mutations. Among all, the germline alteration of the gene coding for E-Cadherin (.) was associated with an increased risk of gastric cancer diffuse-histotype and lobular breast cancer. However, the risk assessment of breast neoplasms and the role of multiple prophylactic procedures in these patie作者: 眨眼 時間: 2025-3-23 00:10
https://doi.org/10.1007/978-3-319-99510-6y, it was introduced 50 years ago to downsize locally advanced (inoperable) BCs. NAT are now widespread and so effective to be used also at the early stage of the disease. NAT are heterogeneous in terms of therapeutic patterns, class of used drugs, dosage, and duration. The poly-chemotherapy regimen作者: 煩躁的女人 時間: 2025-3-23 01:29 作者: 披肩 時間: 2025-3-23 08:49
https://doi.org/10.1007/978-981-15-9158-7f radiotherapy, reviewed with a critical discussion of the evidence from trials investigating adjuvant ultra-hypofractionation and partial breast irradiation for early-stage BC, and the locoregional management of lymph nodes in locally advanced BC. Multiple precision medicine-based approaches have b作者: 兇殘 時間: 2025-3-23 11:24
https://doi.org/10.1007/978-981-15-9158-7caloric intake. While obesity and elevated body mass index are well-reported critical risk factors of BC occurrence, there is an expanding area of oncology assessing the impact of caloric intake and nutritional patterns in patients with cancer. Caloric restriction and fast mimicking alimentary regim作者: growth-factor 時間: 2025-3-23 16:22
https://doi.org/10.1007/978-981-15-9158-7 standard treatment for HR?+?BC. Most patients, however, eventually develop resistance to ET, which limits their effectiveness and poses a major challenge for the management of HR?+?BC. Several mechanisms that contribute to ET resistance have been described. One of the most common mechanisms is the 作者: Amylase 時間: 2025-3-23 21:01 作者: 長處 時間: 2025-3-23 23:45
https://doi.org/10.1007/978-981-15-9158-7surgical and radiotherapy techniques improve local control and symptom management, BM remains associated with a poor prognosis. In addition, the efficacy of currently approved systemic therapies in central nervous system (CNS) compartment is still limited, especially after progression on local thera作者: aneurysm 時間: 2025-3-24 03:15
https://doi.org/10.1007/978-981-15-9158-7ent of breast cancer (BC) has increased the numbers of cancer survivors but with the risk of cardiovascular adverse events (CV-AEs). All drugs can potentially damage the cardiovascular system, with different types of clinical manifestations from ischemic myocardial disease to vasculitis, thrombosis 作者: Antagonism 時間: 2025-3-24 07:24
Recent Results in Cancer Researchatients. The applications of gene sequencing, including next-generation gene sequencing (NGS), have led to numerous questions on how to validate, implement, interpret, prioritize and operationalize precision medicine tools to deliver meaningful and impactful interventions. Limited benefit has been p作者: enchant 時間: 2025-3-24 11:49 作者: deciduous 時間: 2025-3-24 14:59 作者: 過剩 時間: 2025-3-24 20:24 作者: FLACK 時間: 2025-3-25 03:15 作者: Jacket 時間: 2025-3-25 06:51
Mesothelial and Mesothelioma Cell LinesBC patients that express programmed cell death protein-1 (PD-1) in combination with chemotherapy in the first-line setting. ICIs are also being investigated in the neoadjuvant and adjuvant settings for TNBC. This chapter aims to discuss different ICIs used to treat all TNBC stages to date.作者: 制度 時間: 2025-3-25 08:17 作者: 消音器 時間: 2025-3-25 14:07 作者: 滑動 時間: 2025-3-25 17:52 作者: Afflict 時間: 2025-3-25 22:42
Growth Factors and Malignant Mesotheliomaincluding their mechanisms of action, efficacy, and tolerability. Moreover, we have also discussed their therapeutic potential based on combinatorial approaches with other targeted therapies in early and metastatic TNBC.作者: 美色花錢 時間: 2025-3-26 02:46
,Antibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer,including their mechanisms of action, efficacy, and tolerability. Moreover, we have also discussed their therapeutic potential based on combinatorial approaches with other targeted therapies in early and metastatic TNBC.作者: 有常識 時間: 2025-3-26 07:53
Book 2023at enable us to better select personalized approaches in breast cancer management..The closing chapters deal with the challenges of conducting research in the? era of precision medicine forcancer. The book is edited and authored by leading experts in this field and will be of interest for clinicians and scientists alike..作者: AGONY 時間: 2025-3-26 10:12
Novel Therapies on the Horizon,ing whether surgery can be omitted in patients who achieve a complete pathological response. In this chapter, I will review the impact of PST on surgical de-escalation and the data supporting the safety of this approach.作者: 暫時休息 時間: 2025-3-26 16:06 作者: 巧思 時間: 2025-3-26 18:21 作者: 冥想后 時間: 2025-3-27 00:36 作者: Ataxia 時間: 2025-3-27 03:14
The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience,nd formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group “ONCOLLEGE”.作者: 具體 時間: 2025-3-27 09:18
Screening Programs for Breast Cancer: Toward Individualized, Risk-Adapted Strategies of Early Detecives of women found to carry a high-risk mutation (i.e., “cascade testing”) as it is in these individuals for whom such actionable information can result in cancers (and/or cancer deaths) being averted. Moreover, even in the absence of clinical cancer genetics services, as is the case for the immedi作者: 高調(diào) 時間: 2025-3-27 11:03 作者: 果仁 時間: 2025-3-27 16:06 作者: 破裂 時間: 2025-3-27 19:53 作者: 賞心悅目 時間: 2025-3-28 00:19
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer, anti-estrogen drugs and result in constitutive activation of the receptor, even in the absence of estrogens. Epigenetic changes, such as DNA methylation and histone modifications, can also contribute to ET resistance by altering the expression of genes that are involved in estrogen signaling. Under作者: 皮薩 時間: 2025-3-28 03:07 作者: 監(jiān)禁 時間: 2025-3-28 09:42 作者: acrimony 時間: 2025-3-28 11:26 作者: 鍵琴 時間: 2025-3-28 16:24 作者: 鞭子 時間: 2025-3-28 22:24 作者: Aura231 時間: 2025-3-28 23:49 作者: 獨特性 時間: 2025-3-29 06:42
https://doi.org/10.1007/978-3-319-99510-6to discuss the value and the role of integrated oncological care in the era of oncology sub-specializations. Additionally, it sheds light on how the harmonization across the health providers can enhance patient care in this setting.作者: Encumber 時間: 2025-3-29 11:19 作者: Overthrow 時間: 2025-3-29 13:40 作者: allude 時間: 2025-3-29 17:09 作者: 補助 時間: 2025-3-29 21:40
https://doi.org/10.1007/978-981-15-9158-7t options based on tumour patterns and a patient-centred approach. A proper patient’s selection is crucial to derive maximal benefits from a treatment strategy and emerging biomarkers should be integrated along with the HER2 status, which is currently the only validated biomarker in the context of H作者: 忍耐 時間: 2025-3-30 00:58
https://doi.org/10.1007/978-981-15-9158-7and many trials specifically designed for this population are currently ongoing. The BC research community needs to address this call with the final aim of improving the efficacy of systemic therapy in CNS compartment and ultimately preventing the occurrence of BM.作者: 敵意 時間: 2025-3-30 06:47
https://doi.org/10.1007/978-981-15-9158-7ing. The aim of this chapter is to review all types of cardiotoxic manifestations related to novel and old agents approved for treatment of BC patients including chemotherapy, anti-HER2 agents, cyclin-dependent kinase 4/6 inhibitors, PolyADP-ribose polymerase (PARP) inhibitors, antiangiogenic drugs 作者: –scent 時間: 2025-3-30 09:44 作者: 竊喜 時間: 2025-3-30 14:54
,Antibody–Drug Conjugates: A New Therapeutic Approach for Triple-Negative Breast Cancer,erapy. Despite recent advances in drug discovery, its management is still a challenge for clinicians, illuminating the unmet need to develop novel treatment approaches. Antibody–drug conjugates (ADC) are innovative oncology drugs that combine the specificity of monoclonal antibodies and the high eff作者: 聰明 時間: 2025-3-30 17:10 作者: animated 時間: 2025-3-30 23:10 作者: Eclampsia 時間: 2025-3-31 01:35 作者: Collected 時間: 2025-3-31 05:14
Assessment and Response to Neoadjuvant Treatments in Breast Cancer: Current Practice, Response Moniy, it was introduced 50 years ago to downsize locally advanced (inoperable) BCs. NAT are now widespread and so effective to be used also at the early stage of the disease. NAT are heterogeneous in terms of therapeutic patterns, class of used drugs, dosage, and duration. The poly-chemotherapy regimen作者: 蒙太奇 時間: 2025-3-31 10:41
